Gene therapy study for hard-to-treat multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma that has come back or stopped responding to treatment, and tests show the disease is still active.
- You have already tried at least 3 different treatments, including a proteasome inhibitor (like bortezomib), an immunomodulator (like lenalidomide), and a CD38 antibody (like daratumumab).
- You are well enough to be up and about (ECOG score 0 or 1).
- Your blood tests meet certain safety levels (checked by the study doctor).
- You do not have myeloma in the brain or spinal cord, or other related plasma cell disorders like Waldenstrom's macroglobulinemia or amyloidosis.
- You do not have a serious infection needing antibiotics, and you are not taking daily steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
This trial tests a new type of immune cell therapy (called CAR T-cells) designed to treat advanced multiple myeloma that has not responded well to standard treatments. The study focuses on safety and how well your body tolerates this personalized cell therapy.
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
This trial tests a new gene therapy, LVIVO-TaVec200, for people with multiple myeloma that has returned or not responded to other treatments. The goal is to see if it can help control the cancer.
This trial tests a new gene therapy, LVIVO-TaVec400, for people with multiple myeloma that has come back or not responded to treatment. The goal is to see if it can help when other treatments have stopped working.
This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.